To our valued colleagues in medicine, social work, and allied health professions
We extend our gratitude for your interest in psychedelic-assisted therapy. This innovative approach to therapy is still in its early stages of emergence in developed nations, and we believe it offers significant potential for healing. We understand that it may appear unconventional or even questionable to some, prompting the familiar question of evidence, as we have all been trained to inquire.
Here, we would like to offer our colleagues our stance on this pioneering treatment. Our team has undergone specialized training in various types of psychedelics and has spent approximately two years evaluating their potential. We would like to present several compelling points that have led us to open Alethia Psychedelic Assisted Therapy Services. At the end of this page, we have provided you with a set of resources should you wish to dig into some information yourself:

01
Psychedelic medicine, particularly ketamine and psilocybin, has received legal authorization from Health Canada for two specific situations: the treatment of treatment-resistant depression and end-of-life anxiety in palliative patients. Similar approvals exist in many American states and Australia. Most specialists in this area of work believe that the future of these medicines is likely to follow the path of cannabis here in Canada, slowly expanding to address harm reduction and, eventually, available to anyone that feels they might benefit from them.
02
The procurement and distribution of psychedelic medicines in Canada are handled by Filament Health, Health Canada's partner, and incur no cost to patients at this time (https://www.filament.health/). Currently, the medication is transported and stored in compliance with Health Canada approved procedures, right to the prescribing doctors’ office.


03
While psilocybin is the initial psychedelic medicine to be put to use in Canada and the U.S., research trials have progressed more rapidly with MDMA. It is expected that the FDA will grant widespread approval for MDMA use in treating PTSD in the U.S., with other medicines and applications following swiftly. We anticipate this FDA approval within the next two years, but until then, psilocybin remains the sanctioned medicine in Canada.
04
We acknowledge and address doubts and skepticism surrounding this form of treatment. It is essential to remember that the apprehension surrounding psychedelics stems from the "war on drugs" narrative of the 1970s. We advocate for the safe and therapeutic use of psychedelic medicines while respecting their sacred significance in many Indigenous and ancient cultures, where they have offered healing for decades, beyond political disputes.


05
Our commitment to learning is unwavering. As research into these medicines continues to deepen and broaden, we remain at the forefront of this evolving field. We see ourselves as facilitators of the healing potential of these medicines, more than mere interveners.
For those seeking further information, we recommend exploring the following resources:
- MAPS Research Page: https://maps.org/our-research
- Johns Hopkins Center for Psychedelic and Consciousness Research, which includes TED talks by neuroscientists and a timeline of research and regulation: (www.hopkinsmedicine.org/psychiatry/research/psychedelics-research
- Health Canada Information Page: www.canada.ca/en/health-canada/services/substance-use/controlled-illegal-drugs/magic-mushrooms.html
- Government of Canada Press Release announcing funding for research into psilocybin-assisted therapy, including quick facts and links: www.canada.ca/en/institutes-health-research/news/2023/06/government-of-canada-invests-nearly-3-million-to-study-the-potential-benefits-of-psilocybin-assisted-psychotherapy.html
Time article titled "The Future of MDMA, Psilocybin, and Psychedelics in the U.S." https://time.com/6253702/psychedelics-psilocybin-mdma-legalization/
We hope that these resources will provide valuable insights into the promising field of psychedelic-assisted therapy.